Postoperative nausea and vomiting
Adult: Max initial dose: 2.5 mg, may be given via IM/IV admin. Additional doses of 1.25 mg may be given if necessary.
Child: 2-12 yr: Max initial dose of 100 mcg//kg, may be given via IV/IM admin.
Elderly: Dose reduction may be necessary.

Special Populations: Elderly and debilitated patients: Reduced dosage, generally ½ adult dose.
Coma; CNS depression; phaeochromocytoma; bone marrow suppression. Patients at risk of arrhythmias, CV disorders, electrolyte imbalance, preexisting QT prolongation.
Warnings / Precautions
Hepatic or renal impairment; history of jaundice; CV disease; DM; hyperthyroidism; Parkinson's disease; epilepsy, depression, myasthenia gravis; prostatic hypertrophy; severe respiratory disease; blood dyscrasias. May precipitate coma, affect driving. Pregnancy; lactation; elderly.
Adverse Reactions
Dry mouth, constipation, micturition difficulty, blurred vision, mydriasis, delirium, agitation, catatonic-like states, insomnia, nightmares, depression, miosis, convulsions, nasal congestion. CV effects; hypersensitivity reactions, haematological disorders, extrapyramidal dysfunction. Amenorrhoea, galactorrhoea, gynaecomastia, weight gain and hyperglycaemia, and altered glucose tolerance. Pain and irritation at the Inj site. Post-op drowsiness.
Overdose Reactions
Symptoms may include QT prolongation and serious arrhythmias. In the presence of hypoventilation or apnea, oxygen may be used and respiration should be assisted or controlled as needed. Maintain a patent airway. The patient should be under careful observation for 24 hr; ensure adequate body warmth and fluid intake. Hypotension may occur as a result of hypovolemia, may be managed with appropriate parenteral fluid therapy.
Drug Interactions
Avoid concurrent use with drugs that may prolong QT interval e.g. certain antihistamines, antimalarials, calcium-channel blockers and antidepressants. May potentiate the action of other CNS depressants e.g. barbiturates, alcohol. Caution when using with drugs that may induce hypokalaemia or hypomagnesemia.
See Below for More droperidol Drug Interactions
Lab Interactions
Minor abnormalities in liver function tests.
Mechanism of Actions
Droperidol acts mainly at the subcortical levels and exhibits strong sedative effects. It inhibits sympathetic postganglionic α-adrenergic receptor binding sites. It also exhibits antiemetic but has no analgesic effects.
Onset: 3-10 min.
Duration: 2-4 hr.
Storage Conditions
Parenteral: Store at 15-25°C.
ATC Classification
N01AX01 - droperidol ; Belongs to the class of other general anesthetics.
N05AD08 - droperidol ; Belongs to the class of butyrophenone derivatives antipsychotics.
Parenteral: Store at 15-25°C.
Available As
  • Droperidol 2.5 mg
  • Subscribe for latest updates

    Subscribe to our e-mail newsletter to receive updates.

    No comments yet.

    Post Review about Droperidol

    Droperidol Containing Brands

    We are Developing Our database, More results coming soon.

    Droperidol is used in following diseases

    We are Developing Our database, More results coming soon.

    Drug - Drug Interactions of Droperidol

    We are Developing Our database, More results coming soon.